Association of Fatty Liver (Non-Alcoholic), Metabolic Syndrome and Subclinical Inflammation on Mild Renal Inadequacy

2021 ◽  
Vol 15 (12) ◽  
pp. 3159-3160
Author(s):  
Irfana Hassan ◽  
Abdul Rehman Khan ◽  
Syed Ehsanullah
Keyword(s):  
Metabolic Syndrome ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Analytical Study ◽  
Subclinical Inflammation ◽  
Insulin Production ◽  
Alcoholic Fatty Liver ◽  
Medical College ◽  
Alcoholic Fatty Liver Disease

Background: Non-alcoholic liver disease causes liver damage and influences the insulin production, metabolic and inflammatory pathways and renal sufficiency. Aim: To find an association of fatty liver, metabolic syndrome and subclinical inflammation on mild renal inadequacy. Study design: Comparative analytical study Place and duration of study: Department of Medicine, Bolan Medical College Quetta from 1st January 2020 to 30th June 2021. Methodology: One hundred and twenty patients were enrolled. They were divided in two groups; 60 controls and 60 non-alcoholic fatty liver disease patients age between 30-55 years of age included. Their demographic, ultrasonography, anthropometric measurements and biochemical details were recorded. Results: There were 34 men out of 60 having NA fatty liver with a mean age of 45±5.8 years. Mild renal inadequacy was seen in 21, metabolic syndrome in 27, hypertension in 18 and diabetes in 8 of non-alcoholic fatty liver patients with a mean raised CRP as 1.5±0.8mg/L. Conclusion: Non-alcoholic fatty liver presence in addition to metabolic syndrome and subclinical inflammation effect on mild renal inadequacy Key words: Fatty liver, Metabolic syndrome, Subclinical inflammation, Mild renal inadequacy

scholarly journals Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review

Antioxidants ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 270
Author(s):  
Luca Rinaldi ◽  
Pia Clara Pafundi ◽  
Raffaele Galiero ◽  
Alfredo Caturano ◽  
Maria Vittoria Morone ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Risk Factor ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Smoking Habit ◽  
Lifestyle Modifications ◽  
Alcoholic Fatty Liver ◽  
The Metabolic Syndrome ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MS) are two different entities sharing common clinical and physio-pathological features, with insulin resistance (IR) as the most relevant. Large evidence leads to consider it as a risk factor for cardiovascular disease, regardless of age, sex, smoking habit, cholesterolemia, and other elements of MS. Therapeutic strategies remain still unclear, but lifestyle modifications (diet, physical exercise, and weight loss) determine an improvement in IR, MS, and both clinical and histologic liver picture. NAFLD and IR are bidirectionally correlated and, consequently, the development of pre-diabetes and diabetes is the most direct consequence at the extrahepatic level. In turn, type 2 diabetes is a well-known risk factor for multiorgan damage, including an involvement of cardiovascular system, kidney and peripheral nervous system. The increased MS incidence worldwide, above all due to changes in diet and lifestyle, is associated with an equally significant increase in NAFLD, with a subsequent rise in both morbidity and mortality due to both metabolic, hepatic and cardiovascular diseases. Therefore, the slowdown in the increase of the “bad company” constituted by MS and NAFLD, with all the consequent direct and indirect costs, represents one of the main challenges for the National Health Systems.

scholarly journals Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome

2010 ◽  
Vol 69 (2) ◽  
pp. 211-220 ◽  
Author(s):  
J. Bernadette Moore
Keyword(s):  
Metabolic Syndrome ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Response To Treatment ◽  
Health Concern ◽  
Alcoholic Fatty Liver ◽  
The Metabolic Syndrome ◽  
Increased Risk ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is now the most common liver disease in both adults and children worldwide. As a disease spectrum, NAFLD may progress from simple steatosis to steatohepatitis, advanced fibrosis and cirrhosis. An estimated 20–35% of the general population has steatosis, 10% of whom will develop the more progressive non-alcoholic steatohepatitis associated with markedly increased risk of cardiovascular- and liver-related mortality. Development of NAFLD is strongly linked to components of the metabolic syndrome including obesity, insulin resistance, dyslipidaemia and type 2 diabetes. The recognition that NAFLD is an independent risk factor for CVD is a major public health concern. There is a great need for a sensitive non-invasive test for the early detection and assessment of the stage of NAFLD that could also be used to monitor response to treatment. The cellular and molecular aetiology of NAFLD is multi-factorial; genetic polymorphisms influencing NAFLD have been identified and nutrition is a modifiable environmental factor influencing NAFLD progression. Weight loss through diet and exercise is the primary recommendation in the clinical management of NAFLD. The application of systems biology to the identification of NAFLD biomarkers and factors involved in NAFLD progression is an area of promising research.

Sign in / Sign up

Export Citation Format

Share Document